Lantern Pharma Inc. Quarterly Debt-to-equity in % from Q1 2021 to Q3 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Lantern Pharma Inc. quarterly Debt-to-equity history and growth rate from Q1 2021 to Q3 2024.
Lantern Pharma Inc. Debt-to-equity for the quarter ending September 30, 2024 was 11.2 %, a 102% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2024	11.2	+5.66	+102%	Sep 30, 2024
Q2 2024	8.97	+3.39	+60.8%	Jun 30, 2024
Q1 2024	7.18	+0.98	+15.8%	Mar 31, 2024
Q4 2023	5.98	+0.05	+0.84%	Dec 31, 2023
Q3 2023	5.57	+0.15	+2.77%	Sep 30, 2023
Q2 2023	5.58	+0.95	+20.6%	Jun 30, 2023
Q1 2023	6.2	+2.72	+78.2%	Mar 31, 2023
Q4 2022	5.93	+3.39	+133%	Dec 31, 2022
Q3 2022	5.41	+3.03	+127%	Sep 30, 2022
Q2 2022	4.62	+2.07	+81%	Jun 30, 2022
Q1 2022	3.48	+0.23	+7.09%	Mar 31, 2022
Q4 2021	2.54			Dec 31, 2021
Q3 2021	2.39			Sep 30, 2021
Q2 2021	2.55			Jun 30, 2021
Q1 2021	3.24			Mar 31, 2021

* An asterisk sign (*) next to the value indicates that the value is likely invalid.